A phase 1, open-label, dose-escalating study to evaluate the safety, tolerability and immunogenicity of the recombinant plague vaccine rF1V in healthy volunteers.
Phase of Trial: Phase I
Latest Information Update: 16 Oct 2018
At a glance
- Drugs Yersinia pestis vaccine (Primary)
- Indications Plague
- Focus Adverse reactions
- Sponsors DynPort Vaccine Company
- 25 Sep 2008 Status changed from active, no longer recruiting to completed.
- 17 Jan 2007 Status change
- 26 Nov 2005 New trial record.